Guardant Health Says ECLIPSE Study Data Demonstrating Efficacy Of Shield Blood-Based Test For Colorectal Cancer Screening Will Be Published In The New England Journal Of Medicine
Portfolio Pulse from Benzinga Newsdesk
Guardant Health announced that data from its ECLIPSE study, demonstrating the efficacy of its Shield blood-based test for colorectal cancer screening, will be published in The New England Journal of Medicine.
March 13, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health's announcement about the ECLIPSE study results being published in The New England Journal of Medicine is a significant validation of its Shield blood-based test for colorectal cancer screening.
The publication of the ECLIPSE study results in a prestigious journal like The New England Journal of Medicine is a strong endorsement of the Shield test's efficacy. This could lead to increased adoption of the test, potentially boosting Guardant Health's revenues and market position in the cancer screening sector.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100